|  |
| --- |
|  |
| Book Name: | **MEDICINE ESSENTIALS IN CLINICAL PRACTICE** |
| Manuscript Number: | **Ms\_BPR\_4080.4** |
| Title of the Manuscript:  | **APPROACH TO ADULT-ONSET STILLS DISEASE** |
| Type of the Article | **Book chapter** |

|  |
| --- |
| PART 1: Comments |
|  | Reviewer’s comment | Author’s Feedback *(Please correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)* |
| **Please write a few sentences regarding the importance of this manuscript for the scientific community. A minimum of 3-4 sentences may be required for this part.** | 1-This manuscript on Adult-Onset Still’s Disease (AOSD) is significant for the scientific community as it consolidates crucial insights into a rare inflammatory disorder. 2- detailing the epidemiology, etiology, clinical manifestations, diagnostic criteria, and treatment strategies, it aids in the accurate diagnosis and effective management of AOSD. 3- inclusion of differential diagnoses and treatment approaches helps healthcare professionals navigate the complexities of AOSD, potentially improving patient outcomes. 4- the manuscript emphasizes the importance of continued research, raising awareness, and advancing therapeutic options, which are critical for enhancing the understanding and care of this rare disease |  |
| **Is the title of the article suitable?****(If not please suggest an alternative title)** | The current title, "Approach to Adult-Onset Still's Disease," is suitable as it directly addresses the topic and indicates a focus on understanding and managing the condition. However, it can be more descriptive or engaging title, you could consider alternatives like:(**Comprehensive Guide to Adult-Onset Still's Disease: Diagnosis and Management**) |  |
| Is the abstract of the article comprehensive? Do you suggest the addition (or deletion) of some points in this section? Please write your suggestions here. | **The abstract need to be more tidy up here is a suggestion**Adult-Onset Still’s Disease (AOSD) is a rare, serious inflammatory disorder characterized by prolonged fevers, arthritis, with uncommon coloured rash. Although it resembles juvenile idiopathic arthritis, AOSD is diagnosed in patients aged over 16. The disease is fueled by an overactive immune response, known as a “cytokine storm” and can be set off by infectious agents or genetic factors. It commonly presents as fever, rash, and arthritis, while severe cases may develop rare, but severe, complications, such as Macrophage Activation Syndrome (MAS). The diagnosis of AOSD is made according to certain criteria, including the Yamaguchi criteria, while treatment usually consists of anti-inflammatory drugs, steroids, and other biologics to reduce the inflammation and prevent flare-ups. This review will provide a current update on AOSD and will address the pathogenesis, clinical manifestations, diagnosis, and treatment of this disease and the need for early diagnosis with a multidisciplinary approach to treatment. |  |
| **Is the manuscript scientifically, correct? Please write here.**  | Based on my review of the manuscript, I did not find specific errors that explicitly need correction. The information appears consistent with the typical clinical descriptions and management strategies for Adult-Onset Still’s Disease (AOSD). |  |
| **Are the references sufficient and recent? If you have suggestions of additional references, please mention them in the review form.****-** | **To enhance the manuscript's relevance and ensure it reflects the latest advancements in Adult-Onset Still's Disease (AOSD), consider incorporating the following recent references:**1-EULAR/PReS Recommendations for Diagnosis and Management: This 2024 publication provides updated guidelines on diagnosing and managing AOSD, emphasizing the importance of early recognition and treatment strategies <https://ard.bmj.com/content/83/12/1614>2- Advances in Understanding and Treatment: A 2024 review discussing the latest insights into AOSD's pathophysiology and emerging therapeutic options, highlighting new targets under evaluation<https://link.springer.com/article/10.1007/s40265-024-01993-x>3- Efficacy and Safety of Therapies for Still's Disease and Macrophage Activation Syndrome: This 2024 study evaluates the effectiveness of various treatments, noting that IL-1 and IL-6 inhibitors show the highest efficacy in managing Still's disease. <https://ard.bmj.com/content/83/12/1731>4-FDA Approval of Canakinumab for AOSD: In 2020, the FDA approved Ilaris (canakinumab) for treating active Still's disease, including AOSD, marking a significant advancement in therapeutic options<https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-adult-onset-stills-disease-severe-and-rare-disease>5-Current and Emerging Biological Therapy in AOSD: A 2021 article exploring the role of biologic agents in AOSD treatment, discussing the shift from traditional therapies to targeted biologics.<https://academic.oup.com/rheumatology/article-abstract/60/9/3986/6297401>6-Diagnosis and Treatment of Adult-Onset Still's Disease: A Concise Review: This 2022 review offers a succinct overview of AOSD, including diagnostic criteria and treatment modalities, serving as a practical guide for clinicians. <https://link.springer.com/article/10.1007/s00393-022-01294-2>These additions will enhance the manuscript's depth and provide a comprehensive overview of contemporary approaches to AOSD. |  |
| Is the language/English quality of the article suitable for scholarly communications? | The language quality of the article is generally suitable for scholarly communication, as it is clear and uses appropriate medical terminology. |  |
| Optional/General comments | non |  |

|  |
| --- |
| **PART 2:**  |
|  | **Reviewer’s comment** | **Author’s comment** *(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)* |
| **Are there ethical issues in this manuscript?**  | *(If yes, Kindly please write down the ethical issues here in details)* |  |

|  |
| --- |
| **Reviewer Details:** |
| Name: | **Ruaa Maan Attallah** |
| Department, University & Country | **AL-Nahrain University, Iraq** |